Table 2.
Detailed characteristics of the included studies in the meta-analysis, concerning the YKL-40 biomarker for controls and T2DM patients with normoalbuminuria.
| First Author’ s Name, Year (Reference) | Country | Sample Size (n) | Sex (%Male) | Age | Definition of Albuminuria for T2DM Patients | YKL-40 | Method of uKIM-1 Measurement | Variables Provided | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Controls | Patients | Controls | Patients | Controls | Patients | ||||||
| Umapathy D, 2018 [37] | India | 83 | 81 | 52.6 | 60.5 | 54.1 | 54.1 | Normoalbuminuria: uACR < 30 mg/g | Plasma | Immunoassay (Bio-PlexPro™) |
Median + range |
| El-Menshawy N, 2011 [11] | Egypt | 35 | 39 | 54.3 | 48.7 | 49.3 | 52.5 | Normoalbuminuria uACR < 30 mg/g |
Serum | EIA (METRA, QUIDEL) |
Mean + SD |
| Rondbjerg AK, 2011 [38] | Denmark | 20 | 49 | 60.4 | 44.8 | 57.1 | 61.3 | Normoalbuminuria uACR < 22.12 mg/g |
Serum | ELISA (Quidel, USA) |
Median + IQR |
| Zurawska-Plaksej E, 2014 [39] | Poland | 32 | 29 | 37.5 | 37.9 | 61.0 | 62.9 | Normoalbuminuria uACR < 30 mg/g |
Plasma | ELISA (MicroVue, Quidel) |
Mean + SD |
| Han JY, 2015 [40] | China | 210 | 260 | 48.4 | 50.7 | 53.4 | 52.8 | Normoalbuminuria uACR < 30 mg/g |
Serum | ELISA (Bio-Technology) |
Median + IQR |
| Lee JH, 2012 [41] | South Korea | 22 | 25 | 59.1 | 44 | 52.4 | 55.6 | Normoalbuminuria uACR < 30 mg/g |
Plasma | ELISA (R&D Systems) |
Median + IQR |